← All companies

MGX

Metagenomi Therapeutics, Inc.

MGX Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$1.21

-0.01 -0.82%

Key statistics

from XBRL data in SEC filings

Market cap

$45.6M

Revenue (TTM)

$22.3M

Net income (TTM)

-$85.9M

EPS (TTM)

$-2.29

P/E ratio

—

Dividend yield

—

Free cash flow

-$89.5M

Cash

$25.3M

Total assets

$197M

Gross margin

—

52-week range

$1.13 – $3.95

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Director or officer change; Shareholder vote results Jun 10, 2026 10-Q Quarter ended 2026-03-31 May 11, 2026 8-K Results of operations (earnings release); Regulation FD disclosure May 11, 2026 10-K Fiscal year ended 2025-12-31 Mar 5, 2026 8-K Results of operations (earnings release) Mar 5, 2026 8-K Amended charter or bylaws; Regulation FD disclosure Jan 12, 2026 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Nov 12, 2025 8-K Entered a material agreement; Terminated a material agreement Oct 1, 2025 10-Q Quarter ended 2025-06-30 Aug 12, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Aug 12, 2025 8-K Shareholder vote results Jun 11, 2025 8-K Other events May 14, 2025 10-Q Quarter ended 2025-03-31 May 13, 2025 8-K Results of operations (earnings release); Regulation FD disclosure May 13, 2025 8-K Entered a material agreement Mar 17, 2025 8-K Results of operations (earnings release); Regulation FD disclosure Mar 17, 2025 10-K Fiscal year ended 2024-12-31 Mar 17, 2025 8-K Director or officer change; Regulation FD disclosure Jan 16, 2025 8-K Other events Dec 10, 2024 8-K Results of operations (earnings release) Nov 13, 2024 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Other events Sep 3, 2024 8-K Results of operations (earnings release) Aug 14, 2024 10-Q Quarter ended 2024-06-30 Aug 14, 2024 8-K Results of operations (earnings release); Regulation FD disclosure May 14, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 8-K Terminated a material agreement; Results of operations (earnings release); Regulation FD disclosure May 1, 2024 8-K Results of operations (earnings release) Mar 27, 2024 10-K Fiscal year ended 2023-12-31 Mar 27, 2024 8-K Amended charter or bylaws Feb 13, 2024

Other filings

4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 11, 2026 4 Jun 10, 2026 4 Jun 10, 2026 4 Jun 10, 2026 ARS Apr 27, 2026 DEFA14A Apr 27, 2026